Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Booster programme welcome but plans must be in place for boosters for all vaccinated people

09/20/2021 | 10:17am EDT

Health Secretary Sajid Javid has confirmed that a programme of COVID-19 booster vaccinations will begin this week for people 50 and over and those with underlying health conditions. The Harley Street Health Centre has been conducting an ongoing audit on antibody levels in vaccinated people since the vaccination programme began, testing antibody levels over time in the same individuals, using the Roche quantitative antibody test. The audit supports other research on waning vaccine efficacy over time, with steady antibody reduction seen in all participants

The post Booster programme welcome but plans must be in place for boosters for all vaccinated people appeared first on PR Fire.

Health Secretary Sajid Javid has confirmed that a programme of COVID-19 booster vaccinations will begin this week for people 50 and over and those with underlying health conditions.

The Harley Street Health Centre has been conducting an ongoing audit on antibody levels in vaccinated people since the vaccination programme began, testing antibody levels over time in the same individuals, using the Roche quantitative antibody test.

The audit supports other research on waning vaccine efficacy over time, with steady antibody reduction seen in all participants. For some participants who had their first vaccine in the earliest groups, antibodies are no longer detectable.

Clinical director Dr Enam Abood commented,

"Although antibody levels do not tell the whole immunity story, we are concerned that a booster programme for only select groups returns many adults in the UK to a previous vulnerable position, where their ability to fight this virus deteriorates significantly after 6 months to a year. We strongly encourage the government to roll out a nationwide vaccination booster programme, for all vaccinated adults. There is a risk that we undo all of the incredible work achieved over this year and stop impacting transmission and mutations by not being definitive in this action."

She continued,

"Understandably, in the midst of a pandemic, our focus is entirely on preventing hospitalisations and death. But there are a growing number of adults and young people in the UK developing longer term symptoms, that can be life-changing and debilitating, and we cannot allow this to become our norm. We are looking at a future health crisis."

www.harleyhealthcentre.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about ROCHE HOLDING AG
10/15ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E..
BU
10/15ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea..
AQ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq -2-
DJ
10/15PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people..
DJ
10/15GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
DJ
10/15ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists
MT
10/15ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology..
AQ
10/15PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig..
DJ
10/14ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month
RE
10/14ROCHE : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatmen..
PU
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 787 M 66 909 M 66 909 M
Net income 2021 14 572 M 15 780 M 15 780 M
Net cash 2021 4 469 M 4 840 M 4 840 M
P/E ratio 2021 20,9x
Yield 2021 2,60%
Capitalization 313 B 339 B 339 B
EV / Sales 2021 5,00x
EV / Sales 2022 4,86x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 360,25 CHF
Average target price 382,53 CHF
Spread / Average Target 6,19%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG16.59%339 442
JOHNSON & JOHNSON2.49%424 619
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283